BioPharmaChem Ireland welcomes Eli Lilly announcement of new manufacturing facility in Limerick

BioPharmaChem Ireland (BPCI), the Ibec group representing the biopharma sector, welcomes the announcement by Eli Lilly to establish a new manufacturing facility in Limerick today. The company will invest €400 million in the manufacture of biological ingredients which will be used in the production of range of new medicines being developed by the company to treat a range of illnesses including Alzheimer’s disease.
 
Commenting on the announcement BPCI Director, Matt Moran, said: “This is fantastic news for Eli Lilly and for the industry generally. It is a testimony to Ireland’s ability to continue to attract cutting edge investment in the biopharma manufacturing sector. These types of investments are much sought after so it is a real achievement for the company here and for IDA Ireland to secure this. BPCI is ambitious to continue growing the biopharma sector in Ireland, currently valued at €96 billion in exports and employing over 38,000 directly, the same indirectly. This type of investment supports that strategy.
 
“BPCI and its members look forward to working with Eli Lilly to ensure that this investment is a success. I am confident that this will be another major step in the expansion of the biopharma sector in Ireland. Eli Lilly is already a very important employer in the Cork area where they employ 2300 at Kinsale and Little Island.

”